 |
|
|||||||||||||||||||||||||||||
| [发表评论] [本类其他产品] [本类其他供应商] [收藏] | ||||||||||||||||||||||||||||||
| 销售商： 上海基锘威生物科技有限公司 | 查看该公司所有产品 >> |
Design of the EL4-hCD19-LZ cell line
The EL-4 cell line was established from a C57BL/6 murine lymphoma. These cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.
We generated an EL4-hCD19-LZ clonal cell line expressing high levels of human CD19 (NCBI GeneID: 930), and an optimized dual fusion reporter luciferase-ZsGreen (LZ). EL4-hCD19-LZ cells form tumors in vivo when injected subcutaneously. Luciferase-ZsGreen (LZ) control cells are available.
EL4-hCD19-LZ features- Express a fully human CD19
- Express a luciferase-ZsGreen (LZ) fusion reporter
- Form tumors upon subcutaneous injection in fully immunocompetent mice
Expression analysis by flow cytometry. Human CD19 expression was assessed in EL4 parental cell line (left), human control cells – PBMC (center), and EL4-hCD19-LZ cell line (right).
Left figure. Humanized CD3 C57/Bl6 mice were injected (s.c.) with 1x106 EL4-hCD19-LZ cells. Tumor growth was measured every 2 to 4 days. Tumor size (mm3) = (width² x length)/2.
Right figure. Medium (200 mm3) and large (800 mm3) tumors were collected and tumor composition was determined by flow cytometry.
更多详细数据请联系我们：联系我们 - 基锘威 - genOway (my3w.com)
